Red light rebuttal

Research suggesting repeated low-level red-light (RLRL) for treatment of myopia can cause photochemical and thermal damage (News 02.02.24) has been refuted by Eyerising International, which produces a RLRL device cited in the research.

A company statement said its device was referred to in a ‘negative and inaccurate manner’ several times within the research, which was published in Ophthalmic & Physiological Optics Journal.

Eyerising International said the device was not tested during the research, but was still compared to other RLRL devices, which were measured in the researchers’ laboratory.

A company statement said: ‘The Eyerising device has undergone 10 clinical trials and four real world studies, covering 1,785 patients, with a cumulative clinical trial use of nine-and-a-quarter years with zero significant adverse events recorded.